Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
Rhea-AI Summary
Cellectar Biosciences (NASDAQ: CLRB) will report its second quarter 2026 financial results and provide a corporate update on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time. The event will include a conference call and webcast, with a replay available on the company’s Investor Relations Events page.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings report: CLRB +5.11%
Following this news, CLRB has gained 5.11%, reflecting a notable positive market reaction. The stock is currently trading at $2.61.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Earnings date notice | Neutral | -1.3% | Scheduled first-quarter results and conference call for May 14 |
| Feb 25 | Earnings date notice | Neutral | +3.6% | Scheduled full-year results and corporate update for March 4 |
| Nov 06 | Earnings date notice | Neutral | +2.7% | Scheduled third-quarter results and conference call for November 13 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Comparable scheduling notices produced two positive and one negative 24-hour reactions, ranging from -1.29% to +3.57%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Thursday, August 13, 2026 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: | 26325 |
| Webcast: | Click HERE |
A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.
Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.
In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit https://www.cellectar.com/ or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
